ClinicalTrials.gg
Enrolling by invitationNCT07558460Updated Apr 30, 2026

Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial

An interventional study of Virtual Reality Group in Idiopathic Pulmonary Arterial Hypertension, sponsored by Istanbul University - Cerrahpasa. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Motor Activity by Istanbul University - Cerrahpasa — 26 open to participants now, 28 under way, none of them phase 3. Motor Activity · Istanbul University - Cerrahpasa.

Planned enrollment
46th of 62
32 · median 42
Started
2026
with 8 others
No phase
62 of 81
18 open now
Primary completion
2027-01
later than 19 of 27 live
Registered
73rd of 81
by date

Among the 81 studies in Motor Activity by Istanbul University - Cerrahpasa, this one is the 46th largest by planned enrollment of the 62 interventional ones that give a count, is one of 9 that started in 2026, is one of 62 with no phase, reaches primary completion later than 19 of the 27 other live ones, and was the 73rd registered.

Motor Activity

9,827 studies on the registry are indexed under Motor Activity; 1,911 are open to participants now.

Browse Motor Activity studies →

Open to participants now

26 of the 81 studies in Motor Activity by Istanbul University - Cerrahpasa are open now, in 1 country. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Where they have run

Who these studies take

Of the 1,207 Motor Activity studies recruiting now, 524 (43%) set no upper age limit and 538 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Motor Activity by Istanbul University - Cerrahpasa, or all of them as a file.
02

Study summary

The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject. The main question is whether exercises delivered via immersive virtual reality are effective to improve physical performance, functional capacity, dyspnea, muscle strength, fatigue, quality of life, depression and anxiety.

Read the detailed description

The number of studies examining the effects of exercise training in pulmonary hypertension (PH) is limited in the literature. Given the chronic nature of PH and the benefits of exercise in PH, the importance of exercise programs that include motivation as a factor becomes apparent. Therefore, the aim of this research is to investigate the effectiveness of exercise programs implemented via virtual reality under the supervision of a physiotherapist in PH patients. To investigators' knowledge, there are no studies in the literature examining the effectiveness of exercise training conducted via virtual reality in PH patients. Therefore, another aim of this research is to identify virtual reality (VR) applications that can be used to improve clinical outcomes in PH patients and to contribute to the literature on the effectiveness of using innovative technologies in rehabilitation programs.

03

Conditions studied

  • Idiopathic Pulmonary Arterial Hypertension

Browse trials for

Keywords

  • idiopathic pulmonary arterial hypertension
  • immersive virtual reality
  • exercise
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Idiopathic Pulmonary Arterial Hypertension,
  • Stable pharmacological treatment for the past 3 months,
  • Hemodynamic and clinical stability for at least the past three months,
  • Age of 18-65,
  • Voluntary participation in the study and signing the form,
  • Being classified in the World Health Organization-Functional Classification I, II or III.

Exclusion criteria

Exclusion Criteria:

  • The presence of an orthopedic or neurological problem that will affect functional tests and muscle strength measurement,
  • Acute decompensated heart failure,
  • Unstable angina pectoris,
  • Uncontrolled hypertension,
  • The presence of problems that hinder communication,
  • Dizziness, vertigo,
  • Severe visual impairment,
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Virtual Reality Group

    Patients assigned to Group 1 are involved in supervised exercise sessions 3 times a week during 8 weeks. Exercise sessions includes aerobic and strengthed exercises delivered via virtual reality

    Other: Virtual Reality Group

  • No intervention
    Control Group

    Patients assigned to Group 2 will not included any intervention

Interventions

  • OtherVirtual Reality Group

    Patients assigned to Group 2 are involved in supervised exercise sessions 3 times a week during 8 weeks. Exercise sessions includes aerobic and strengthed exercises delivered via virtual reality

06

What researchers measure

Primary outcomes

  1. Muscle Strength

    Lower and upper extremity strength: Measurement is performed by having the person being tested exert maximum effort against the device during the measurement, and the person conducting the test respond with maximum force in the opposite direction to prevent movement. The tests are repeated three times, and the average of the values is recorded in Newtons (N).

    Time frame: at the beginning of the study and at the end of 8 week,

  2. Hand Grip Strength

    The tests will be repeated three times, and the average of the values will be recorded in kilograms of force (kgF).

    Time frame: at the beginning of the study and at the end of 8 weeks

  3. Functional capacity of lower extremity

    Six Minute Walking Test: Participants will be asked to walk as fast as possible at their own pace for 6 minutes on a 30-meter course. The distance walked by the patient will be recorded in meters.

    Time frame: at the beginning of the study and at the end of 8 weeks

  4. Functional capacity of upper extremity

    Six Minute Pegboard and Ring Test: A wooden platform with bars will be used during the test. Two bars will be placed at shoulder level and the other two 20 cm above shoulder level. Ten rings, each weighing 14 grams, will be placed on the lower bars: ten on the right and ten on the left, for a total of 20 rings. Patients will be asked to place as many rings as possible from the lower bars to the upper bars and then back to the lower bars using both hands for 6 minutes. At the end of this time, the number of rings moved will be recorded as the the total score, and the resting time will be recorded in seconds.

    Time frame: at the beginning of the study and at the end of 8 weeks

  5. Physical performance

    Short Physical Performance Battery: The test consists of 3 tests: walking 4 meters, standing up from a chair, and standing balance test. Each test is scored between 0-4. The scores obtained by the participants, ranging from 1-4, indicate the progressive performance required to complete the test according to the specified times. Walking test: Participants will be asked to walk 4 meters in a pre-marked corridor, and the time will be recorded and scored. The use of walking aids will be permitted, and saturation monitoring will be performed. Standing up from a chair test: Participants will be asked to stand up once from a seated position with their arms crossed over their chest. Patients who can do this will be asked to stand up and sit down five times as quickly as possible, and the time will be recorded. Standing balance test: 3 positions will be used; feet side-by-side and together, tandem, and half-tandem.

    Time frame: at the beginning of the study and at the end of 8 weeks

Secondary outcomes

  1. Dyspnea assessment

    Modified Medical Research Council Dyspnea Scale: This scale was developed to assess the level of dyspnea in patients. The scale evaluates how much difficulty patients experience in daily life activities due to dyspnea. Individuals indicate the degree of shortness of breath with a score between 0 and 4. Higher scores indicate a greater perception of dyspnea.

    Time frame: at the beginning of the study and at the end of the 8 weeks

  2. Physical Activity Level Assessment

    International Physical Activity Questionnaire - Short Form: This is a 7-question questionnaire developed to determine physical activity levels, covering the past week. The questionnaire examines activities under the headings of vigorous physical activity, moderate physical activity, and walking. All activities are recorded in terms of frequency (days/week) and duration (minutes/day). A score in MET-min/week is calculated for all categories using a defined metabolic equivalent (MET) per activity, and the sum of these scores gives the total IPAQ-SF score. Standard MET values are accepted as 3.3 for walking, 4.0 for moderate activity, and 8.0 for vigorous activity. Sitting is assessed with a separate question and is not included in the total IPAQ-SF score.

    Time frame: at the beginning of the study and at the end of 8 weeks

  3. Fatigue Assessment

    Fatigue Severity Scale: The scale consists of 9 questions, each rated between 1 (strongly disagree) and 7 (strongly agree). The total value is divided by 9 to obtain the final score. An increased score indicates greater fatigue severity. A score of \<2.8 indicates no fatigue, while a score \>6.1 indicates chronic fatigue.

    Time frame: at the beginning of the study and at the end of 8 weeks

  4. Quality of life assessment

    EmPHasis 10: Developed for assessing quality of life in patients diagnosed with pulmonary hypertension, the EmPHasis-10 includes inquiries about significant consequences of the disease, such as shortness of breath, fatigue, and lack of energy, which can also affect social life. The scale consists of 10 questions, each a Likert-type question scored between 0 and 5. The total score of the scale ranges from 0 to 50 points. A high score indicates a poor quality of life due to symptoms.

    Time frame: at the beginning of the study and at the end of 8 weeks

  5. Depression and anxiety assessment

    Hospital Anxiety and Depression Scale: The scale consists of 14 questions in total. The Likert-type scale includes 7 questions to assess anxiety levels and 7 questions to assess depression levels. Scores for both sub-assessments range from 0 to 21. Higher scores indicate a worse level. For both sub-assessments, scores of 0-7 indicate a normal level, 8-10 indicate borderline mood disorder, and ≥11 indicate a mood disorder.

    Time frame: at the beginning of the study and at the end of the 8 weeks

  6. Virtual Reality Experience Assessment

    Simulator Sickness Questionnaire: This is a scale that assesses the safety of experiences that alter the perception of reality, such as virtual reality, and the symptoms of motion sickness. It consists of 16 items grouped into 3 subscales (oculomotor symptoms, disorientation, nausea). Each item is rated on a four-point scale (0 = I feel nothing, 1 = somewhat, 2 = moderate, and 3 = very), and the total score is the sum of the scores of the three subscales.

    Time frame: at the beginning of the study and at the end of the 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 5,176 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 12 months is below that.

Counting every sponsor, half of 5,236 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
Apr 30, 2026
StartActual
Jan 31, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07558460
Responsible party
Gamze Öztürk (physiotherapist, Istanbul University - Cerrahpasa) — Principal investigator
First posted
Apr 30, 2026
Start date
Jan 31, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Apr 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion